Literature DB >> 33572979

Association of RANKL and OPG Gene Polymorphism in Arab Women with and without Osteoporosis.

Saba Abdi1, Rawan A Binbaz1, Abdul Khader Mohammed1,2, Mohammed G A Ansari2, Kaiser Wani1, Osama E Amer1, Abdullah M Alnaami1, Naji Aljohani1,3, Nasser M Al-Daghri1.   

Abstract

Receptor activator of the nuclear factor-κB ligand (RANKL) and osteoprotegerin genes (OPG) were identified as susceptible loci for postmenopausal osteoporosis (PMO) in various ethnicities, but neither have been studied in an Arabian population. Hence, the current study aimed to fill this gap. A total of 372 postmenopausal women (174 osteoporosis (OP) and 198 control group (CTRs)) were genotyped for four SNPs: rs2277438A/G and rs9533156T/C (RANKL), and rs2073618C/G and rs3102735T/C (OPG). Anthropometrics, bone mineral density, 25(OH)D and several other bone markers were measured. The frequency distribution of the heterozygous CG genotype of rs2073618 (OPG) was lower in the OP (36.8%) than in CTRs (47%) (OR: 0.6, 95% CI: 0.3-0.97; p = 0.041). No differences in the allelic/genotypic frequencies were detected between the two groups for all other studied SNPs. However, the heterozygous TC genotype of rs3102735 (OPG) was associated significantly with lower BMD at the femoral neck in OP subjects (p = 0.04). The homozygous rare CC genotype of rs9533156 (RANKL) was associated with lower 25(OH)D levels in CTRs (p = 0.032). In contrast, heterozygous AG genotype of rs2277438 (RANKL) is associated with lower 25(OH)D in the OP group (p = 0.02). Our results suggest that RANKL SNPs may impact 25(OH)D levels and that OPG SNP rs2073618A/G is a significant genetic risk factor for PMO Saudi Arabian women.

Entities:  

Keywords:  RANKL/OPG; Saudi postmenopausal women; rs2073618; rs2277438; rs3102735; rs9533156; single nucleotide polymorphism

Year:  2021        PMID: 33572979      PMCID: PMC7910965          DOI: 10.3390/genes12020200

Source DB:  PubMed          Journal:  Genes (Basel)        ISSN: 2073-4425            Impact factor:   4.096


  56 in total

Review 1.  Pathogenesis of osteoporosis: concepts, conflicts, and prospects.

Authors:  Lawrence G Raisz
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

2.  A variance component approach to dichotomous trait linkage analysis using a threshold model.

Authors:  R Duggirala; J T Williams; S Williams-Blangero; J Blangero
Journal:  Genet Epidemiol       Date:  1997       Impact factor: 2.135

3.  Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis.

Authors:  K Yano; E Tsuda; N Washida; F Kobayashi; M Goto; A Harada; K Ikeda; K Higashio; Y Yamada
Journal:  J Bone Miner Res       Date:  1999-04       Impact factor: 6.741

4.  Polymorphisms in genes in the RANKL/RANK/OPG pathway are associated with bone mineral density at different skeletal sites in post-menopausal women.

Authors:  P Tu; P Duan; R-S Zhang; D-B Xu; Y Wang; H-P Wu; Y-H Liu; L Si
Journal:  Osteoporos Int       Date:  2014-08-20       Impact factor: 4.507

5.  Efficacy of vitamin D supplementation according to vitamin D-binding protein polymorphisms.

Authors:  Nasser M Al-Daghri; Abdul Khader Mohammed; Ihtisham Bukhari; Maryam Rikli; Saba Abdi; Mohammed Ghouse Ahmed Ansari; Shaun Sabico; Syed Danish Hussain; Amal Alenad; Yousef Al-Saleh; Majed S Alokail
Journal:  Nutrition       Date:  2019-02-19       Impact factor: 4.008

6.  Association analyses of RANKL/RANK/OPG gene polymorphisms with femoral neck compression strength index variation in Caucasians.

Authors:  Shan-Shan Dong; Xiao-Gang Liu; Yuan Chen; Yan Guo; Liang Wang; Jian Zhao; Dong-Hai Xiong; Xiang-Hong Xu; Robert R Recker; Hong-Wen Deng
Journal:  Calcif Tissue Int       Date:  2009-05-21       Impact factor: 4.333

7.  Polymorphisms in the osteoprotegerin gene are associated with osteoporotic fractures.

Authors:  Bente L Langdahl; Mette Carstens; Liselotte Stenkjaer; Erik Fink Eriksen
Journal:  J Bone Miner Res       Date:  2002-07       Impact factor: 6.741

Review 8.  Genetic control of susceptibility to osteoporosis.

Authors:  Stuart H Ralston
Journal:  J Clin Endocrinol Metab       Date:  2002-06       Impact factor: 5.958

Review 9.  Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss.

Authors:  Anne-Priscille Trouvin; Vincent Goëb
Journal:  Clin Interv Aging       Date:  2010-11-19       Impact factor: 4.458

10.  Role of RANKL-RANK/osteoprotegerin molecular complex in bone remodeling and its immunopathologic implications.

Authors:  Sarvraj Singh Kohli; Virinder Singh Kohli
Journal:  Indian J Endocrinol Metab       Date:  2011-07
View more
  4 in total

1.  PTHR1 Genetic Polymorphisms Are Associated with Osteoporosis among Postmenopausal Arab Women.

Authors:  Saba Abdi; Abeer Abdulaziz Almiman; Mohammed Ghouse Ahmed Ansari; Abdullah M Alnaami; Abdul Khader Mohammed; Naji J Aljohani; Amal Alenad; Amani Alghamdi; Majed S Alokail; Nasser M Al-Daghri
Journal:  Biomed Res Int       Date:  2021-12-22       Impact factor: 3.411

2.  Osteoprotegerin Gene Polymorphisms Are Associated with Subclinical Atherosclerosis in the Mexican Mestizo Population.

Authors:  Benny Giovanni Cazarín-Santos; Nonanzit Pérez-Hernández; Rosalinda Posadas-Sánchez; Gilberto Vargas-Alarcón; Óscar Pérez-Méndez; Juan Rodríguez-Silverio; Bladimir Roque-Ramírez; Verónica Marusa Borgonio-Cuadra; José Manuel Rodríguez-Pérez
Journal:  Diagnostics (Basel)       Date:  2022-06-10

Review 3.  Pharmacogenomics of Monoclonal Antibodies for the Treatment of Rheumatoid Arthritis.

Authors:  Sung Ho Lim; Khangyoo Kim; Chang-Ik Choi
Journal:  J Pers Med       Date:  2022-07-31

4.  Vitamin D Receptor Gene Variants Susceptible to Osteoporosis in Arab Post-Menopausal Women.

Authors:  Mohammed G A Ansari; Abdul Khader Mohammed; Kaiser A Wani; Syed D Hussain; Abdullah M Alnaami; Saba Abdi; Naji J Aljohani; Nasser M Al-Daghri
Journal:  Curr Issues Mol Biol       Date:  2021-09-27       Impact factor: 2.976

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.